Pseudotype Production Optimization

伪型生产优化

• 批准号: 6708087
• 负责人: Benjamin Jacob Doranz
• 金额: $ 40.77万
• 依托单位: INTEGRAL MOLECULAR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-02-15 至 2006-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6708087
• 关键词: Adenoviridae; G protein; Retroviridae; SDS polyacrylamide gel electrophoresis; biosensor device; cell membrane; drug discovery /isolation; enzyme linked immunosorbent assay; lipid bilayer membrane; membrane proteins; method development; protein binding; protein purification; protein structure function; receptor coupling; receptor expression; tissue /cell culture; transfection /expression vector; transmission electron microscopy

DESCRIPTION (provided by applicant): ViraCore is a tool-based biotechnology company that is creating a drug discovery platform for use by the pharmaceutical and biotechnology industries. ViraCore is developing "lipoparticles", nanometer-sized particles surrounded by a lipid bilayer and embedded with membrane-bound receptors, to purify and solubilize complex receptors from the cell surface while maintaining their structural integrity. ViraCore intends to leverage this technology for drug discovery and research of integral membrane proteins on biosensors and other microfluidic devices. Approximately half of the drugs in use today target membrane proteins, including G-protein coupled receptors. The purpose of this proposal is to scale lipoparticle production techniques, modify and improve lipoparticle properties, begin development of second-generation lipoparticles with unique capabilities, and validate lipoparticles for drug discovery applications. The goals of this proposal are to: - Optimize Commercial Manufacture Protocols - Develop Second- generation Lipoparticles - Improve Lipoparticle Composition - Validate Lipoparticles as Drug Screening Reagents

描述（由申请人提供）： ViraCore是一家基于工具的生物技术公司，正在创建一个药物发现平台，供制药和生物技术行业使用。ViraCore正在开发“脂质颗粒”，即被脂质双层包围并嵌入膜结合受体的纳米颗粒，以从细胞表面纯化和溶解复杂受体，同时保持其结构完整性。ViraCore打算利用这项技术进行药物发现和生物传感器和其他微流体设备上的整合膜蛋白的研究。目前使用的药物中大约有一半是针对膜蛋白的，包括G蛋白偶联受体。该提案的目的是扩大脂质体生产技术，修改和改善脂质体性质，开始开发具有独特能力的第二代脂质体，并验证用于药物发现应用的脂质体。该提案的目标是： - 优化商业生产方案 - 第二代脂质体的研制 - 改善脂肪颗粒成分 - 脂质体作为药物筛选试剂